Pfizer: Credit Suisse still a buyer
(CercleFinance.com) - Credit Suisse maintains its Outperform rating on Pfizer shares, along with a target price of 55 dollars (share closed down 2% at 49.
7 dollars yesterday).
"We believe that consensus is substantially underestimating the potential for four key assets: Lyme disease vaccine, respiratory syncytial virus (RSV) vaccine, a messenger RNA (mRNA) influenza vaccine, and danuglipron," the analyst says.
These could potentially be first-in-class products, "particularly danuglipron, the first small molecule GLP-1 inhibitor," Credit Suisse notes.
"We are 19% above the Street by 2030, forecasting adjusted pipeline of $12.9bn vs. cons. of $10.8bn," the analyst, before noting that, " Risks include: macro conditions continuing to deteriorate, pricing headwinds, pipeline risk to clinical trials, and COVID-related sales likely declining further".
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.